Ventricular tachycardia and myocardial infarction during antiarrhythmic therapy: a case report
https://doi.org/10.20996/1819-6446-2023-2914
EDN: TFOVWD
Abstract
The article analyzes the case of the development of ventricular tachycardia and type 2 myocardial infarction (MI) in an 80-year-old patient with a history of coronary artery disease, MI and chronic heart failure. In 2020, the patient was diagnosed with ventricular extrasystole and started antiarrhythmic therapy with diethylamino propionylethoxycarbonylaminophenothiazine 150 mg per day and sotalol 160 mg per day. In 2022, the patient had an episode of clinical death due to ventricular tachycardia with successful resuscitation. A diagnosis of non-ST-elevation acute coronary syndrome was made, coronary angiography was performed, which did not reveal significant coronary stenosis. Upon further examination, the dynamics of biomarkers of myocardial necrosis confirmed the diagnosis of acute MI. In the analyzed case, the development of ventricular tachycardia and MI is most likely associated with the intake of diethylaminopropionylethoxycarbonylaminophenothiazine in combination with sotalol, prescribed in the presence of contraindications to their use.
About the Authors
A. A. Gurbanova
Ryazan State Medical University
Russian Federation
Russian Federation
Arzu A. Gurbanova
Ryazan
K. G. Pereverzeva
Ryazan State Medical University
Russian Federation
Russian Federation
Kristina G. Pereverzeva
Ryazan
S. S. Yakushin
Ryazan State Medical University
Russian Federation
Russian Federation
Sergey S. Yakushin
Ryazan
I. V. Budanova
Ryazan State Medical University
Russian Federation
Russian Federation
Irina V. Budanova
Ryazan
References
1. Fourth universal definition of myocardial infarction (2018). Russian Journal of Cardiology. 2019;(3):107-138 (In Russ.) DOI:10.15829/1560-4071-2019-3-107-138.
2. Lebedev DS, Mikhailov EN, Neminuschiy NM, et al. Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. Russian Journal of Cardiology. 2021;26(7):4600. (In Russ.) DOI:10.15829/1560-4071-2021-4600.
3. Leonova MV. Drug-induced arrhythmias. Medical Council. 2020;(21):26-40 (In Russ.) DOI:10.21518/2079-701X-2020-21-26-40.
4. Sychev DA, Ostroumov OD, Kochetkov AI, eds. Drug-Induced Diseases / Edited by — M.: Prometheus, 2022 (In Russ.)
5. Tsaregorodcev DA. The problem of drug-resistant arrhythmias. Russian Journal of Cardiology. 2001;(2):68-75 (In Russ.)
6. Barbarash OL, Duplyakov DV, Zateischikov DA, et al. 2020 Clinical practice guidelines for Acute coronary syndrome without ST segment elevation. Russian Journal of Cardiology. 2021;26(4):4449. (In Russ.) DOI:10.15829/1560-4071-2021-4449].
7. Yakushin SS, Nikulina NN, Seleznev SV. Myocardial infarction. M.: GEOTAR- Media, 2018. (In Russ.) [Якушин С. С., Никулина Н. Н., Селезнев С. В. Инфаркт миокарда. М.: ГЭОТАР-Медиа, 2018.].
8. Averkov OV, Barbarash OL, Boytsov SA, et al. Differentiated approach in diagnostics, diagnosis formulation, case management and statistical accounting of type 2 myocardial infarction (Position Paper). Russian Journal of Cardiology. 2019;(6):7-21 (In Russ.) DOI:10.15829/1560-4071-2019-6-7-21].
9. Iskenderov BG, Lokhina TV, Minkin AA. Differential diagnosis of ischemic myocardial damage against the background of continuous pacing. Russian journal of cardiology. 2003;(3):15-18. (In Russ.)
10. Molyanova A. A., Nikulina N. N. The prognostichesky importance of infringe- ments of the rhythm and conductivity at sick of the myocardial infarction. I. P. Pavlov Russian Medical Biological Herald. 2012;20(1):138-143 (In Russ.) DOI:10.17816/PAVLOVJ20121138-143].
11. Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) DOI:10.15829/1560-4071-2020-4083].
12. Khasaeva EI, Deulina LE. Side effects of drugs. Studnet 2022;5(5):10 (in Russ).
13. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhy- thmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406412. DOI: 10.1056/NEJM198908103210629.
14. Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhy- thmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327(4):227-233. DOI:10.1056/NEJM199207233270403.
15. Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Pharmateka. 2020;27(6):113-126 (In Russ.) DOI:10.18565/pharmateca.2020.6.113-126].
Supplementary files
Review
For citations:
Gurbanova A.A., Pereverzeva K.G., Yakushin S.S., Budanova I.V. Ventricular tachycardia and myocardial infarction during antiarrhythmic therapy: a case report. Rational Pharmacotherapy in Cardiology. 2023;19(3):264-269. (In Russ.) https://doi.org/10.20996/1819-6446-2023-2914. EDN: TFOVWD
Views: 177
Email this article 